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Results from epidemiologic studies examining pancreatic cancer risk and vitamin D intake or 25-hydroxyvitamin
D (25(OH)D) concentrations (the best indicator of vitamin D derived from diet and sun) have been inconsistent.
Therefore, the authors conducted a pooled nested case-control study of participants from 8 cohorts within the
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP) (1974–2006) to evaluate whether pre-
diagnostic circulating 25(OH)D concentrations were associated with the development of pancreatic cancer. In
total, 952 incident pancreatic adenocarcinoma cases occurred among participants (median follow-up, 6.5 years).
Controls (n ¼ 1,333) were matched to each case by cohort, age, sex, race/ethnicity, date of blood draw, and follow-
up time. Conditional logistic regression analysis was used to calculate smoking-, body mass index-, and diabetes-
adjusted odds ratios and 95% conﬁdence intervals for pancreatic cancer. Clinically relevant 25(OH)D cutpoints
were compared with a referent category of 50–<75 nmol/L. No signiﬁcant associations were observed for partic-
ipants with lower 25(OH)D status. However, a high 25(OH)D concentration ( 100 nmol/L) was associated with
a statistically signiﬁcant 2-fold increase in pancreatic cancer risk overall (odds ratio ¼ 2.12, 95% conﬁdence
interval: 1.23, 3.64). Given this result, recommendations to increase vitamin D concentrations in healthy persons
for the prevention of cancer should be carefully considered.
case-control studies; cohort studies; pancreatic neoplasms; prospective studies; vitamin D
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CI, conﬁdence interval; CPS-II, Cancer Pre-
vention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NIST, National Institute of Standards and Technology;
NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D3, 1,25-dihydroxyvitamin
D3; OR, odds ratio; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study;
SWHS, Shanghai Women’s Health Study; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
Sun exposure has been associated with lower death rates
for pancreatic cancer in several ecologic studies (1–7).
Solar ultraviolet B radiation (280–320 nm) induces cuta-
neous production of precursors of vitamin D and is the
primary contributor to vitamin D status in most populations
(1, 2, 4, 6). Dietary sources of vitamin D include cholecal-
ciferol (vitamin D3), which occurs naturally in some ani-
mal foods (e.g., fatty saltwater ﬁsh, liver, and eggs).
Supplements and fortiﬁed foods such as milk, orange juice,
and margarine contain vitamin D3 produced by the irradi-
ation of 7-dehydrocholesterol extracted from lanolin or
vitamin D2 (ergocalciferol) obtained from plants (8–10).
25-Hydroxyvitamin D (25(OH)D) is the main circulating
form of vitamin D in humans and is considered the best
81 Am J Epidemiol 2010;172:81–93assessment of vitamin D status derived from both sun
exposure and diet.
Animal and cell culture studies support vitamin D
having a function in the pancreas. Expression of the en-
zyme 25-hydroxyvitamin D3-1a-hydroxylase, which con-
verts 25(OH)D to 1,25-dihydroxyvitamin D, the bioactive
form of the vitamin, has been detected in normal and ad-
enocarcinomatous tissue and normal pancreatic duct cells
(11–13). 25-Hydroxyvitamin D3 hinders pancreatic cancer
cell line growth (12, 13). 1,25-Dihydroxyvitamin D ana-
logs in vitro stimulate differentiation, promote apoptosis,
impede pancreatic cancer cell proliferation (14–16), and
in vivo inhibit pancreatic tumor growth (16, 17). There
is evidence that vitamin D regulates insulin synthesis, bind-
ing, and response (18–20). Experimental and epidemiologic
studies support that higher insulin and glucose levels
and diabetes contribute to pancreatic cancer development
(21–24).
However, epidemiologic studies examining dietary vita-
min D, a predicted 25(OH)D status score, or measured
25(OH)D concentrations and pancreatic cancer have
shown conﬂicting results. Two prospective studies demon-
strated reduced risk for pancreatic cancer with higher total
vitamin D intake (25) and predicted vitamin D status score
computed from 6 determinants of 25(OH)D concentrations
(dietary and supplementary vitamin D, skin pigmentation,
adiposity, geographic residence, and leisure activity) (26).
Those studies’ limitation was that vitamin D status was not
measured in participants. Conversely, a nested case-control
study carried out in the Alpha-Tocopherol, Beta-Carotene
(ATBC) Cancer Prevention Study population, a cohort of
male Finnish smokers, showed an unexpected and statisti-
cally signiﬁcant 3-fold increased risk of pancreatic cancer
with higher vitamin D levels (27). The results of the ATBC
study may not be comparable to nonsmokers, women, or
populations residing at latitudes lower than Finland with
higher vitamin D status (27). A subsequent nested case-
control study carried out in a US population, the Prostate,
Lung, Colorectal and Ovarian (PLCO) Cancer Screening
Trial cohort, did not conﬁrm the strong positive association
between 25(OH)D and pancreatic cancer overall (28).
However, the latter study did show an increased risk among
participants living at northern latitudes that was similar to
the ATBC ﬁndings (27).
Given the inconsistent results from the studies examining
vitamin D concentrations and pancreatic cancer, we con-
ducted a pooled nested case-control study of participants
from 8 cohorts in the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers (VDPP) to test whether
prediagnostic circulating 25(OH)D concentrations were as-
sociated with subsequent risk of incident pancreatic cancer.
Because the VDPP pooled data on cohorts from multiple
geographic regions, latitudes, seasons, and ethnic popula-
tions, the present investigation had more cases and a wider
range of vitamin D concentrations than the previous
studies.
MATERIALS AND METHODS
Study design and population
This pooled nested case-control study included data from
the following cohort studies: the ATBC Study (29), CLUE
(30), the Cancer Prevention Study II Nutrition Cohort (CPS-
II) (31), the New York University Women’s Health Study
(NYU-WHS) (32), the Multiethnic Cohort Study (MEC)
(33), the PLCO (34), and the Shanghai Women’s and Men’s
Health Studies (SWHS and SMHS) (35, 36) (Table 1). The
ﬁnal analytic data set included 952 cases and 1,333 controls
from these 8 cohorts.
Table 1. Characteristics of Cohorts Included in an Investigation of Circulating 25-
Hydroxyvitamin D Concentrations and Pancreatic Cancer, by Cohort, Cohort Consortium Vitamin









Median Circulating 25-Hydroxyvitamin D
Concentration, nmol/L (Range)
Cases Controls
ATBC 313 513 9.4 (5.5–13.0) 43.6 (2.1–150.9) 43.0 (2.6–126.9)
CLUE 123 123 10.6 (5.7–15.2) 57.8 (9.0–141.1) 56.4 (5.7–111.1)
CPS-II 65 65 2.2 (1.3–3.2) 55.8 (14.1–115.3) 60.2 (16.6–112.3)
MEC 109 109 2.1 (1.3–3.5) 49.5 (2.0–137.6) 47.7 (5.2–115.9)
NYU-WHS 73 73 13.5 (8.6–17.0) 47.2 (16.1–156.0) 46.8 (6.5–127.2)
PLCO 183 364 5.6 (2.8–7.7) 64.7 (13.2–135.5) 65.1 (16.3–126.0)
SMHS 27 27 1.5 (0.9–2.7) 38.8 (13.3–82.0) 40.3 (9.2–85.4)
SWHS 59 59 5.5 (2.1–6.7) 33.4 (8.7–63.5) 30.4 (14.5–79.5)
Total 952 1,333 6.5 (2.8–10.9) 49.3 (2.0–156.0) 50.8 (2.6–127.2)
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II,
Cancer Prevention Study II; IQR, interquartile range; MEC, Multiethnic Cohort Study; NYU-WHS,
New York University Women’s Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s
Health Study.
a 25th–75th percentiles.
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nomas (International Classiﬁcation of Diseases for Oncol-
ogy, Third Edition, codes C250–C259 or C25.0–C25.3 and
C25.7–C25.9). Endocrine pancreatic tumors (International
Classiﬁcation of Diseases for Oncology, Third Edition, code
C25.4; histology types 8150, 8151, 8153, 8155, and 8240)
were excluded, because the etiology of these cancers is
thought to be different. Case ascertainment varied between
studies but included linking participants to cancer registries,
self- and next-of-kin reports, and use of national death
indices.
Controls were selected with a control:case ratio of 1:1
(ATBC, CLUE, CPS-II, NYU-WHS, MEC, SMHS, and
SWHS) or 2:1 (ATBC and PLCO) and were alive and free
from pancreatic cancer on the date on which the matched
case was diagnosed. Data from cases and controls from the
previously published ATBC (27) and PLCO (28) nested
case-control studies were included in the present analysis.
Controls were matched to cases on age and date of blood
draw, sex, and race/ethnicity. For some cohorts, controls
were additionally matched on other factors, such as fasting
status at blood draw, time of blood draw, and, for women,
menopausal status.
Data on lifestyle, demographic factors, and possible
confounders were collected. Detailed descriptions of data
collection methods have been published previously for
the individual studies (29–36). From each cohort, infor-
mation was obtained on history of cigarette smoking, sex,
age, race/ethnicity, body mass index (weight (kg)/height
(m)
2), family history of pancreatic cancer, diet, alcohol
consumption, self-reported pancreatitis, and diabetes
history.
Informed consent was obtained in each of the individual
studies. Each study was approved by its local institutional
review board.
Measurement of circulating 25(OH)D
Samples from CLUE, CPS-II, NYU-WHS, MEC, SMHS,
and SWHS and a subset of samples from the ATBC Study
were sent to Heartland Assays, Inc. (Ames, Iowa) and as-
sayed for 25(OH)D status using the DiaSorin LIAISON 25
OH Vitamin D TOTAL Assay (DiaSorin, Inc., Stillwater,
Minnesota) (37). The ATBC and PLCO samples had
25(OH)D measured using the same method in the labora-
tory of Dr. Reinhold Vieth (Mount Sinai Hospital, Toronto,
Ontario, Canada) or at Heartland Assays, Inc., at an earlier
time (2005 and 2007), respectively (27, 28). Matched case
and control samples were masked to case status and were
assayed consecutively within batches. The US National In-
stitute of Standards and Technology (NIST) provided 2
masked serum quality control standards for vitamin D to
include within batches: NIST level 1 (~60 nmol/L) and
NIST level 2 (~35 nmol/L). Quality control samples were
also provided by investigators from the individual cohorts.
For the VDPP samples, the interbatch and intrabatch co-
efﬁcient of variation percentages for NIST level 1 samples
were 12.7% and 9.3%, respectively, and for NIST level 2
samples, they were 13.6% and 11.0%, respectively. The
median inter- and intrabatch coefﬁcient of variation per-
centages for the cohort quality control samples were
13.2% (range, 4.8%–17.0%) and 9.9% (range, 3.8%–
16.4%), respectively. Using a nested components of vari-
ance analysis, with logarithmically transformed quality
control measurements across all batches (38), the overall
(intra- and interbatch) coefﬁcient of variation percentages
were 16.5% and 4.7% for the previously assayed 25(OH)D
concentrations in the ATBC and PLCO studies, respectively
(27, 28).
Statistical analysis
The distributions of selected characteristics of the cases
and controls were compared using conditional logistic re-
gression. Dietary nutrients and foods highly correlated
with energy intake were energy-adjusted using the residual
method described by Willett and Stampfer (39). Variables
examined in analyses and/or as potential confounders in
risk models were age; smoking status at the time of blood
draw and most recently (never smoker, former smoker who
hadquit 15years previously,formersmokerwhohadquit
1–14 years previously, former smoker who had quit <1
year previously or current smoker of <20 cigarettes/day,
and former smoker who had quit <1 year previously
or current smoker of  20 cigarettes/day); education;
hormone use (among women); height; weight; body mass
index (<25, 25–<30, or  30, or missing data); history of
diabetes (yes, no, or missing data); family history of pan-
creatic cancer; intake of vitamin D-containing foods (ﬁsh,
milk); nutrients from foods (energy, carbohydrate, fat, sat-
urated fat, calcium, vitamin D, folate, and retinol); nutri-
ents from supplements (folic acid, vitamin D, and
calcium); total nutrients (folate, vitamin D, and calcium);
consumption of red or processed meat; use of multivita-
mins (yes, no, or missing data); alcohol consumption;
physical activity; season of blood draw (winter, summer);
and latitude at study entry. Seasons were deﬁned as winter
(December–May) and summer (June–November).
Clinically deﬁned 25(OH)D cutpoints were used for the
main analyses: <25, 25–<37.5, 37.5–<50, 50–<75,
75–<100, and  100 nmol/L (40, 41). Conditional logistic
regression was used to calculate odds ratios and 95% con-
ﬁdence intervals for pancreatic cancer by 25(OH)D level,
with 50–<75 nmol/L used as the referent category. Multi-
variable models were developed by individually adding
covariates to the model with forward and backward selec-
tion. Covariates were included if they were associated with
both the disease and the risk factor and changed the point
estimate of risk by 10% or more. The ﬁnal multivariable
models included body mass index and smoking (as cate-
gorized above). Interactions were evaluated in stratiﬁed
analyses, by sex, race/ethnicity, season, latitude, smoking
status (never, former, or current; never vs. ever), body
mass index (<25 vs.  25), and use of vitamin D supple-
ments or multivitamins; statistical signiﬁcance was tested
using a multiplicative risk model. Conditional logistic re-
gression was used to calculate odds ratios stratiﬁed by sex
and race/ethnicity, while unconditional logistic regression,
adjusted for matching factors, was used for the other
stratiﬁcations.
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Gallicchio et al. (42) was conducted. Results are presented
for high ( 100 nmol/L) or low (<25 nmol/L) 25(OH)D
concentrations as compared with the reference category
(50–<75 nmol/L). The heterogeneity of cohort-speciﬁc
estimates was assessed using the Q statistic, and data are
presented as forest plots. To investigate whether 1 single
study unduly inﬂuenced the pooled estimates, we conducted
Table 2. Selected Characteristics of Cases and Controls in an Investigation of Circulating 25-Hydroxyvitamin D Concentrations and Pancreatic
Cancer, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, 1974–2006
Characteristic
Cases (n 5 952) Controls (n 5 1,333)
P Value
b
No. % Median (IQR
a) No. % Median (IQR)
Age, years 62 (56–68) 62 (57–67) Matched
Male sex 602 63.2 919 68.9 Matched
Serum 25(OH)D concentration, nmol/L 49.3 (34.1–66.9) 50.8 (35.7–67.5) 0.18
<37.5 279 19.3 366 27.5 0.53
<25 115 12.1 141 10.6 0.79
Latitude at study entry, degrees North
Total 40.7 (38.6–60.0) 42.4 (39.5–60.0) 0.39
>42 (low sun exposure) 424 44.5 694 52.1 0.39
35–42 (moderate sun exposure) 311 32.7 404 30.3
<35 (high sun exposure) 217 22.8 235 17.6
Race/ethnicity
White 729 76.6 1,095 82.1 Matched
Black 51 5.4 56 4.2
Asian 125 13.1 133 10.0
Other 34 3.6 34 2.6
Missing data 13 1.4 15 1.1
Cigarette smoking history
c
Never smoker 297 46.5 418 51.0 <0.0001
Former smoker 209 32.7 313 38.2
Current smoker 119 18.6 74 9.0
Missing data 14 2.2 15 1.8
Height, cm
Male 175 (170–180) 175 (170–179) 0.50
Female 160 (156–165.1) 160 (157–165.1) 0.57
Body mass index
d 25.7 (23.4–28.4) 26.0 (23.5–28.5) 0.61
<25.0 373 39.2 503 37.7 0.56
25.0–<30 372 39.1 563 42.2
 30 149 15.7 207 15.5
Missing data 58 6.1 60 4.5
History of diabetes mellitus
Yes 78 8.2 102 7.7 0.50
Missing data 23 2.4 21 1.6
Family history of pancreatic cancer
Yes 33 3.5 27 2.0 0.09
Missing data 272 28.6 348 71.9
Education
Less than high school 256 26.9 327 24.5 0.07
High school graduation 166 17.4 197 14.8
Post-high school, vocational training 147 15.4 280 21
Some college 179 18.8 253 19
Table continues
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assessed and compared after systematically excluding each
study in turn. Sensitivity analyses were also conducted after
excluding both the ATBC and PLCO cohorts, for which
reports had been previously published (27, 28). To evaluate
the potential inﬂuence of preclinical disease on risk, we
Table 2. Continued
Characteristic
Cases (n 5 952) Controls (n 5 1,333)
P Value
b
No. % Median (IQR
a) No. % Median (IQR)
College graduation 102 10.7 126 9.5
Postgraduate study 73 7.7 133 10
Missing data 29 3.0 17 1.3
Recent multivitamin use
Yes 156 16.4 203 15.2 0.44




e 23.3 (11.7–40.1) 24.8 (13–43.5) 0.03
Milk, g
e 224 (60.0–485.3) 248.8 (101.7–549.6) 0.93
Red meat (energy-adjusted), g
e 52.8 (36.3–72.8) 51.9 (35.5–72.4) 0.22
Processed meat (energy-adjusted), g
f 26.9 (12.5–45.5) 26.6 (11.4–45.7) 0.06
Alcohol, g
g 2.1 (0–13.7) 2.4 (0–14) 0.21
Nutrients
Energy, kcal
e 1,979.3 (1,497.3–2,602) 2,107.8 (1,524–2,733.7) 0.50
Total fat (energy-adjusted), g
e 81.7 (65.3–93.5) 79.9 (64.9–93.4) 0.09
Saturated fat (energy-adjusted), g
e 29.3 (20.8–38.5) 28.5 (21.1–37.8) 0.03
Carbohydrate (energy-adjusted), g
e 260.8 (231.2–297.9) 268.2 (235.3–299.4) 0.01
Retinol (energy-adjusted), IU
h 1,928.6 (1,036.0–3,265.4) 2,098.8 (1,239.3–3,422.4) 0.94
Folate (energy-adjusted), lg
e 298 (248.2–376.9) 309 (252.8–377.4) 0.05
Vitamin D
Food (energy-adjusted), IU
e 153.6 (102.1–223.2) 165.6 (110.4–233.0) 0.24
Total vitamin D, IU
i 218.4 (142–475.9) 232.9 (152.3–491.5) 0.46
Calcium
Food (energy-adjusted), mg
e 906.9 (711.3–1,104.8) 940.6 (731.3–1,164.8) 0.31
Total, mg
j 1,089.7 (727.2–1,490) 1,159.6 (791.3–1,572.8) 0.12
Quartile of physical activity
Low/none 310 32.6 435 32.6 0.12
Light 285 29.9 418 31.4
Moderate 113 11.9 143 10.7
Vigorous 125 13.1 219 16.4
Missing data 119 12.5 118 8.9
Abbreviations: IQR, interquartile range; 25(OH)D, 25-hydroxyvitamin D.
a 25th–75th percentiles.
b Wald P value from conditional logistic regression.
c Cases and controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study were excluded because they were all current
smokers at baseline.
d Weight (kg)/height (m)
2; World Health Organization categories were used.
e Complete data on dietary intake were available for 855 cases and 1,200 controls; 97 cases and 133 controls had missing data. Numbers differ
slightly from the total for some exposures because of missing data across categories.
f Complete data on dietary intake were available for 769 cases and 1,114 controls; 183 cases and 219 controls had missing data.
g Complete data on alcohol consumption were available for 842 cases and 1,190 controls; 110 cases and 143 controls had missing data.
h Complete data on retinol intake were available for 682 cases and 861 controls; 270 cases and 472 controls had missing data.
i Complete data on total vitamin D intake were available for 575 cases and 915 controls; 377 cases and 418 controls had missing data.
j Complete data on total calcium intake were available for 725 cases and 1,067 controls; 227 cases and 266 controls had missing data.
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during either the ﬁrst 2 years of follow-up or the ﬁrst 5 years
of follow-up.
All statistical analyses were performed using SAS
software, versions 9.1.3 and 9.2 (SAS Institute, Inc.,
Cary, North Carolina) and R software, version 2.8.1
(R Foundation for Statistical Computing, Vienna, Austria
(http://www.r-project.org/)). Statistical tests were 2-tailed.
RESULTS
The characteristics of participants in each cohort are
shown in Table 1. Cases were diagnosed with pancreatic
cancer after a median of 6.5 years of follow-up (range,
0–30.6 years). The median age at pancreatic cancer di-
agnosis was 69.5 years. The range of 25(OH)D concentra-
tions varied across the cohorts, with the SMHS and SWHS
participants having the lowest concentrations and the
PLCO participants having the highest concentrations.
All cases had a higher upper range of 25(OH)D concen-
trations than did the controls, except for those in the
Shanghai cohorts. The ranges of 25(OH)D concentrations
were 2.0–156.0 nmol/L in cases and 2.6–127.2 nmol/L in
controls.
Characteristics of cases and controls are shown in Table 2.
The ATBC participants were excluded from the analysis of
smoking status in Table 2, because all participants in that
study were current smokers at baseline. Compared with the
controls, cases more often reported being a current smoker
(P < 0.0001), had a greater saturated fat intake, and con-
sumed less ﬁsh, carbohydrate, and folate. The proportions of
cases and controls with vitamin D concentrations less than
37.5 nmol/L or less than 25 nmol/L were not statistically
different.
Compared with 25(OH)D concentrations of 50.0–<75.0
nmol/L, concentrations of 100 nmol/L or higher were as-
sociated with increased pancreatic cancer risk (Table 3)(in
the fully adjusted model, odds ratio (OR) ¼ 2.12, 95%
conﬁdence interval (CI): 1.23, 3.64). No statistically sig-
niﬁcant associations were observed for concentrations
of <25.0 nmol/L or 25.0–<37.5 nmol/L, overall or in
stratiﬁed models. The increased risk in the highest cate-
gory of 25(OH)D persisted after exclusion of cases that
occurred within the ﬁrst 2 years after blood draw (leaving
772 cases and 1,115 controls; OR ¼ 2.20, 95% CI: 1.22,
3.96) and cases diagnosed within the ﬁrst 5 years after
blood draw (leaving 558 cases and 840 controls; OR ¼
2.26, 95% CI: 1.13, 4.52). Analyses restricted to US co-
horts showed similar risk in the highest 25(OH)D category
(OR ¼ 2.98, 95% CI: 1.48, 6.02). Similar odds ratios were
observed for analyses that excluded each cohort in turn:
excluding ATBC, 2.95 (95% CI: 1.47, 5.93); excluding
CLUE, 1.75 (95% CI: 0.97, 3.16); excluding CPS-II,
2.32 (95% CI: 1.32, 4.06); excluding MEC, 2.20 (95%
CI: 1.25, 3.86); excluding NYU-WHS, 2.20 (95% CI:
1.26, 3.81); excluding PLCO, 1.60 (95% CI: 0.83, 3.08),
and excluding SMHS/SWHS, 2.12 (95% CI: 1.23, 3.65).
The odds ratio for pancreatic cancer in the highest
25(OH)D category was 2.23 (95% CI: 0.82, 6.08) after
exclusion of the ATBC and PLCO cohorts for which
results had been previously published (n ¼ 496 cases
and n ¼ 886 controls in the analysis) (27, 28).
Associations did not vary signiﬁcantly by sex, season,
race/ethnicity, latitude, smoking status (Table 4), body
mass index, or use of vitamin D supplements or multivita-
mins (P-interaction > 0.15). However, the increased risk
associated with high 25(OH)D concentrations was more
a p p a r e n ti nm a l e st h a ni nf e m a l e s ,w a ss e e no n l yi nb l o o d
samples drawn during the summer and in Caucasians but
not Asians, was statistically signiﬁcant only for latitudes of
35 N–42 N (though it was suggestive for latitudes  42 N),
and was not affected by smoking status. Although the num-
ber of Asians was not large (125 cases, 133 controls), the
pattern of the association appeared different in this
Table 3. Odds Ratios for the Association Between Circulating 25-Hydroxyvitamin D Concentrations and Risk of Pancreatic Cancer
a, Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers, 1974–2006
Model















OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Crude
d 0.98 0.70, 1.35 0.97 0.74, 1.26 1.06 0.84, 1.34 1.00 Referent 1.01 0.77, 1.33 2.05 1.21, 3.48
Multivariate-adjusted
e,f 0.95 0.68, 1.32 0.98 0.75, 1.28 1.04 0.82, 1.33 1.00 Referent 1.02 0.77, 1.35 2.12 1.23, 3.64
Multivariate-adjusted
e,g,h 1.00 Referent 1.04 0.74, 1.44 1.10 0.79, 1.55 1.06 0.76, 1.48 1.08 0.73, 1.59 2.24 1.22, 4.12
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a The analysis included a total of 952 cases and 1,333 controls.
b Categories were based on a priori cutpoints.
c Number of cases/number of controls.
d Adjusted for matching variables (age, race/ethnicity, sex, cohort, and date of blood draw) using conditional logistic regression.
e Additionally adjusted for body mass index (weight (kg)/height (m)
2) in World Health Organization categories (<18.5, 18.5–<25.0, 25.0–30.0,
30.0–<35.0, or  35.0, or missing data), smoking (never smoker, former smoker who had quit  15 yearspreviously, former smoker who had quit 1–
14 years previously, former smoker who had quit <1 year previously or current smoker of <20 cigarettes/day, and former smoker who had quit <1
year previously or current smoker of  20 cigarettes/day), and diabetes status (yes, no, or missing data).
f Reference category: 50.0–<75.0 nmol/L.
g Reference category: <25 nmol/L.
h P for trend ¼ 0.14.
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concentrations of 25(OH)D (odds ratios were 1.30, 1.65,
and 1.54 for progressively lower concentrations in compar-
ison with the referent category). In adjusted models, no
strata showed statistically signiﬁcant trends across the
25(OH) categories, although among men, P-trend was
0.09 and among former smokers, P-trend was 0.14. Among
the small number of African Americans (51 cases, 56 con-
trols) and based on their race/ethnicity-speciﬁc 25(OH)D
distribution, the adjusted odds ratio for the highest third of
25(OH)D levels ( 4 2 . 2n m o l / L )a sc o m p a r e dw i t ht h e
lowest third (<28.2 nmol/L) was 1.77 (95% CI: 0.49,
6.42). There was no statistically signiﬁcant interaction by
use of vitamin D supplements or multivitamins. Among
nonusers of multivitamins (406 cases, 534 controls), as
compared with the reference group, the odds ratios
were 0.83, 1.12, 1.10, 1.01, and 4.19 (95% CI: 1.73,
10.16) from the lowest 25(OH)D concentrations to the
highest, respectively.
There was no signiﬁcant heterogeneity among cohorts
(Figure 1; Q statistic: P > 0.30). The odds ratios from
the meta-analysis for high and low 25(OH)D status, as
compared with the referent group, were 2.14 (95%
CI: 0.93, 4.92) and 0.96 (95% CI: 0.66, 1.40), respectively.
Although the magnitudes of the risks were similar, the
pooled odds ratio (Table 3) was more precise (i.e., a nar-
rower conﬁdence interval) than the odds ratio from the
meta-analysis (Figure 1).
DISCUSSION
The ﬁndings from this pooled nested case-control study
of data from 8 cohorts do not support the hypothesis that
higher circulating vitamin D concentrations reduce the risk
of pancreatic cancer. Indeed, a statistically signiﬁcant 2-
fold increased risk of pancreatic cancer was observed
among subjects with circulating 25(OH)D concentrations
greater than or equalto100nmol/Las comparedwiththose
with 25(OH)D concentrations of 50–<75 nmol/L. The pos-
itive association persisted when each cohort was excluded
from the analysis in turn. The association was independent
of race/ethnicity, sex, smoking history, obesity, and diabe-
tes. Positive associations were observed in men, women,
smokers, never smokers, and nonusers of multivitamin
supplements. Although there were no statistically signiﬁ-
cant interactions, positive associations appeared more pro-
nounced in Caucasians, participants residing in areas at
latitudes above 35 N, and those who had their blood col-
lected during the summer months. No signiﬁcant associa-
tions were observed among participants with lower
25(OH)D status.
These pooled results are consistent with previously
published ﬁndings from both the ATBC (27) and PLCO
(28) cohorts, as all showed some evidence of positive
associations, and effects appeared stronger among per-
sons residing at high latitudes. In the previous nested
case-control study conducted in the ATBC cohort, a pop-
ulation of male Finnish smokers, prediagnostic serum
25(OH)D concentrations greater than 65.5 nmol/L were
associated with a nearly 3-fold increased risk of pancre-
atic cancer compared with concentrations of 32.0 nmol/L
or less (OR ¼ 2.92, 95% CI: 1.56, 5.48; P-trend ¼ 0.001)
(27). Although the previous PLCO nested case-control
study showed an overall non-statistically signiﬁcant
45% increased risk of pancreatic cancer for the highest
ﬁfth of 25(OH)D concentrations as compared with the
lowest ﬁfth, statistically signiﬁcant 4-fold increased risks
were observed with increasing 25(OH)D concentrations
(>78.4 nmol/L vs. <49.3 nmol/L) only among partici-
pants living at northern US latitudes (i.e., Michigan, Min-
nesota, and Wisconsin) (28). Persons who live at low
latitudes with warm, sunlit environments might maintain
efﬁcient vitamin D status throughout the year (28, 43).
This could contribute to more within-person variability
in ambulatory populations and attenuate risk estimates
(28). Further, participants in the Shanghai and MEC stud-
ies, who lived at low latitudes, tended to have lower
25(OH)D concentrations overall (i.e., Shanghai) or because
of race/ethnicity (e.g., African Americans). As a result, few
participants residing at low latitudes had 25(OH)D concen-
trations greater than 100 nmol/L (Table 4; 5 cases and 8
controls), which limited our statistical power to observe
associations.
The present analysis differs from the previous 2 studies
(27, 28) in that clinically relevant vitamin D status cutpoints
were used to examine associations, with 50–<75 nmol/L
being used as the referent category, rather than quintiles
based on the distribution among study controls (27, 28). In
the current pooled analysis, a threshold pattern of associa-
tion was observed, with an increased risk being seen only at
the highest vitamin D concentrations ( 100 nmol/L), which
corresponds to the top 2.3% of the distribution in the con-
trols. In contrast, the previous ATBC Study showed a signif-
icant positive trend with increasing quintiles of vitamin D
concentration (27). On average, men in the ATBC Study had
lower 25(OH)D concentrations than those of the US-based
cohorts (Table 1), and in a range where positive associations
were not observed in the VDPP. Few ATBC participants
were in the high 25(OH)D category ( 100 nmol/L). Exclud-
ing the ATBC participants from the present analysis in-
creased the strength of the association (>100 nmol/L vs.
50–<75 nmol/L: OR ¼ 2.95, 95% CI: 1.47, 5.93), because
the ATBC men were removed from the referent category.
Therefore, the increased pancreatic cancer risk with high
vitamin D status in the present pooled study is not explained
by the ATBC Study participants. The PLCO Study contrib-
uted 19% of the cases (n ¼ 183) and 27% of the controls
(n ¼ 364), with both cases and controls having higher
25(OH)D concentrations than the other cohorts (Table 1).
With the PLCO participants excluded, the association re-
mained positive but nonsigniﬁcant because of reduced study
power (OR ¼ 1.60, 95% CI: 0.83, 3.08). Excluding both the
ATBC and PLCO participants (52% of the cases and 67% of
the controls) resulted in no change in the strength of the
association, but the signiﬁcance was diminished (OR ¼
2.23, 95% CI: 0.82, 6.08) also because of reduced statistical
power. The VDPP’s advantage for examining pancreatic
cancer is the ‘‘pooling’’ of data from 8 cohorts covering
multiple geographic regions, which in total includes a larger
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Status, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, 1974–2006
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CO OR 95% CI No. of
CA
No. of
CO OR 95% CI
Sex
Male 602 919 72 94 91 154 134 199 191 306 83 142 31 24
Crude
d 0.92 0.60, 1.40 0.84 0.60, 1.18 1.05 0.79, 1.40 0.94 0.68, 1.31 2.25 1.23, 4.12
M-A
e 0.87 0.56, 1.34 0.81 0.57, 1.14 1.05 0.79, 1.41 0.95 0.68, 1.32 2.33 1.24, 4.36 0.27
Female 350 414 43 47 73 71 74 87 115 152 37 48 8 9
Crude
d 1.10 0.66, 1.85 1.23 0.79, 1.91 1.07 0.71, 1.61 1.18 0.72, 1.93 1.40 0.45, 4.29
M-A




Winter 489 698 89 103 98 153 110 165 145 218 41 49 6 10
Crude
g 1.26 0.86, 1.83 0.92 0.65, 1.30 1.01 0.73, 1.40 1.35 0.84, 2.18 0.92 0.32, 2.62
M-A
e,g 1.22 0.83, 1.79 0.92 0.65, 1.31 1.00 0.72, 1.40 1.37 0.85, 2.23 0.90 0.31, 2.60 0.21
Summer 463 635 26 38 66 72 98 121 161 240 79 141 33 23
Crude
g 0.89 0.51, 1.57 1.27 0.84, 1.91 1.19 0.84, 1.68 0.91 0.64, 1.29 2.36 1.32, 4.23
M-A
e,g 0.82 0.46, 1.45 1.21 0.80, 1.85 1.19 0.84, 1.69 0.93 0.65, 1.33 2.29 1.26, 4.15
Race/ethnicity
Caucasian 729 1,095 76 101 108 160 157 231 251 402 100 174 37 27
Crude
d 0.97 0.65, 1.43 1.02 0.75, 1.39 1.09 0.84, 1.41 0.96 0.72, 1.28 2.46 1.40, 4.33
M-A
e 0.93 0.63, 1.40 1.00 0.73, 1.37 1.06 0.81, 1.39 0.94 0.70, 1.28 2.43 1.36, 4.35
Asian 125 133 20 21 38 31 29 31 28 33 10 17
Crude
d 1.23 0.49, 3.07 1.46 0.67, 3.19 1.13 0.55, 2.31 0.81 0.30, 2.20
M-A
e 1.54 0.56, 4.20 1.65 0.69, 3.92 1.30 0.58, 2.90 1.08 0.37, 3.17 0.20
Latitude,
degrees North
<35 217 235 32 30 51 50 48 51 59 71 22 25 5 8
Crude
g 1.19 0.61, 2.31 1.15 0.65, 2.03 1.06 0.62, 1.84 1.18 0.59, 2.35 0.98 0.28, 3.36
M-A
e,g 1.19 0.60, 2.36 1.18 0.66, 2.12 1.08 0.61, 1.90 1.31 0.63, 2.69 0.99 0.28, 3.52 0.21
35–42 311 404 24 26 46 49 62 74 119 170 42 76 18 9
Crude
g 1.15 0.61, 2.16 1.27 0.78, 2.07 1.19 0.78, 1.82 0.85 0.54, 1.35 2.89 1.23, 6.77
M-A
e,g 0.97 0.50, 1.88 1.19 0.72, 1.96 1.13 0.73, 1.74 0.86 0.54, 1.38 2.79 1.16, 6.71
>42 424 694 59 85 67 126 98 161 128 217 56 89 16 16
Crude
g 1.16 0.77, 1.77 0.89 0.61, 1.31 1.04 0.74, 1.46 1.12 0.75, 1.69 1.76 0.85, 3.67
M-A




















































3number of cases and a wider range of vitamin D concentra-
tions than the individual studies alone and provides greater
power to observe associations.
A major strength of the VDPP is the prospective design,
thereby reducing the likelihood of reverse causality. In ad-
dition, the cohort study investigators followed a protocol for
case-control selection, and 25(OH)D levels were measured
centrally at the same laboratory (except in the ATBC
Study). Conclusions concerning associations among
Asians or African Americans separately are limited be-
cause of their small numbers in the present analysis. The
measurement of serum 25(OH)D concentration reﬂects in-
ternal dose and actual vitamin D status and is considered
more valid than evaluation of vitamin D intake alone or
predictors of vitamin D status. Although a single measure
of 25(OH)D in adulthood may not correspond to long-term
vitamin D status, it can reﬂect exposure over the past sev-
eral weeks or months (44). In addition, high intraclass
correlations ranging from 0.70 to 0.78 have been observed
in both men and women for measures taken over several
years(45,46),suggestingthat1samplemayprovideagood
measure of long-term status. Controls were matched to
the cases by month of blood collection to reduce misclas-
siﬁcation of vitamin D status due to seasonal variation.
Residual confounding by cigarette smoking is not likely,
because there was no signiﬁcant interaction of the vitamin
D association with smoking status, and positive associa-
tions were observed among never smokers. Both men and
women were included in this study, as well as never, for-
mer, and current smokers; therefore, our results should be
generalizable to Caucasian populations.
The biologic basis for the observed associations is spec-
ulative, because there is an incomplete understanding of the
molecular mechanisms by which the vitamin D receptor–
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) complex regu-
lates the expression of genes involved in pancreatic
carcinogenesis. The active form of vitamin D is a steroid
hormone, and it is likely that the vitamin D receptor–
1,25(OH)2D3 complex affects and interacts with other reg-
ulators and endogenous hormones (47), particularly in an
autocrine or paracrine manner within the pancreas and/or
pancreatic tumor tissue. The active form of vitamin D,
1,25(OH)2D3, might inﬂuence growth factors (19, 20, 48)
which promote tumor growth (27). Toxic effects of hyper-
vitaminosis D are thought to be mediated through hypercal-
cemia, including calciﬁcation of soft tissues; however, the
range of 25(OH)D levels associated with risk in this study
was below that considered to reﬂect hypervitaminosis D
(400–1,250 nmol/L) (49). Alternatively, a mechanism di-
rectly related to solar ultraviolet radiation or an unknown
surrogate risk factor that is correlated with sun exposure is
possible.
In conclusion, the previously reported positive association
between 25(OH)D and pancreatic cancer observed in the ear-
lier studies (27, 28) was conﬁrmed in this large pooled study;
however, the increased risk was observed only among sub-
jects with the highest circulating 25(OH)D concentrations.
Before any conclusions regarding vitamin D’s potential
role(s) in the etiology of pancreatic cancer can be reached,
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Odds Ratio
Cohort OR (95% CI) Cases
ATBC 0.81 (0.48, 1.37)
CLUE 0.85 (0.27, 2.67)
CPS-II 1.16 (0.15, 8.79)
MEC 2.98 (0.84, 10.5)
NYU-WHS 1.28 (0.32, 5.18)
PLCO 0.53 (0.14, 2.02)















Overall 0.96 (0.66, 1.40)
A)
Decreased Risk Increased Risk
Pancreatic Cancer
0.86 (0.06, 12.2)
0.125 0.25 0.50 1 2 4 8
Odds Ratio
Cohort OR (95% CI) Cases
ATBC 1.13 (0.44, 2.91)
CLUE 9.13 (0.95, 87.4)
CPS-II 0.65 (0.03, 15.6)
MEC
NYU-WHS 1.97 (0.08, 48.3)














Overall 2.14 (0.93, 4.92)
B)
Decreased Risk Increased Risk
Pancreatic Cancer
Controls Controls
Figure 1. Forest plots for meta-analysis of the association between circulating 25-hydroxyvitamin D (25(OH)D) concentrations and risk of pancreatic cancer within the Cohort Consortium
Vitamin D Pooling Project of Rarer Cancers, 1974–2006. Odds ratios (squares) and 95% conﬁdence intervals (bars) were derived from conditional logistic regression models adjusted for body
mass index (weight (kg)/height (m)
2) in World Health Organization categories (<18.5, 18.5–<25.0, 25.0–30.0, 30.0–<35.0, or  35.0, or missing data), smoking (never smoker, former smoker
who had quit  15 years previously, former smoker who had quit 1–14 years previously, former smoker who had quit <1 year previously or current smoker of <20 cigarettes/day, and former
smoker who had quit <1 year previously or current smoker of  20 cigarettes/day), and diabetes status (yes, no, or missing data). The size of each square is inversely proportional to the
variance of the log odds ratio estimate in each cohort. The pooled estimates (diamonds) were derived from a meta-analysis using random-effects modeling. For each cohort, the plots show
estimates for subjects with circulating 25(OH)D concentrations of A) <25 nmol/L and B)  100 nmol/L in comparison with the reference group (50–<75 nmol/L). ATBC, Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study, CI, conﬁdence interval; CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NYU-WHS, New York University Women’s
Health Study; OR, odds ratio; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SM/WHS, Shanghai Men’s Health Study and Shanghai Women’s Health Study. SM/WHS




















































3laboratory investigations of biologically plausible mecha-
nisms that may explain the observations. Given the present
study’s pooled results and research gaps in the understanding
of vitamin D’s role in carcinogenesis, recommendations to
increase vitamin D concentrations in healthy persons for can-
cer prevention seem premature.
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